Glycosylation is a complex form of post-translational modification that affects more than 50% of cellular proteins and is a key regulator of many eukaryotic processes. Aberrant glycosylation is a common feature of many cancers and plays a crucial role in all stages of tumor development. Different mechanisms of aberrant glycosylation lead to the formation of tumor-associated glycan antigens (TACA) suitable for selective tumor-targeted therapy. Among tumor-associated glycan antigens, Globo antigens are specifically expressed on pluripotent stem cells and many types of tumor cells, and cancer cells. Thus, globo antigens can serve as a source for the development of novel clinical biomarkers that provide a range of specific targets for therapeutic interventions and a prerequisite for the development of relevant vaccines.
Fig.1 Structure of tumor-associated globo H antigen. (Mandal, et al., 2015)
CD BioGlyco has developed a Vaccine Development Platform dedicated to the Development of Carbohydrate Vaccines. In this type of vaccine development, we provide services such as the development of tumor-related vaccines and the production of tumor-related antigens. Specifically, we produce tumor-associated antigens including but not limited to.
Fig.2 Types of Globo antigens we synthesize. (CD BioGlyco)
CD BioGlyco focuses on the development of carbohydrate vaccines. We have successfully mastered the production of tumor-associated Globo antigens. If you are interested in our services, please feel free to contact us.
References
